CD8+ T cells that recognize KRAS G12V5–14 have been isolated from peripheral blood of HLA-A*02:01+ healthy donors and patients with pancreatic cancer and shown to kill tumor cells, albeit at very high effector to target ratios (Kubuschok et al. 2006, Rive et al. 2020). Here, KRAS is linked to familial pancreatic carcinoma.